PMC10063871_01
Timeline of clinical manifestations and treatments. RnGH, recombinant human growth hormone; MTX, methotrexate. *Treatment with rhGH was temporally discontinued for 15 months due to a diagnosis of ganglioneuroma.
fped-11-1102382-g003.jpg
PMC10063871_02_fped-11-1102382-g003.jpg
F3
At the last follow-up, 9 months later, the child experienced inactivity of arthritis and uveitis with normal growth (Figure 3).
PMC10063871_02
Knee ultrasound of case 2 showing active synovitis.  , Power Doppler signal of synovial tissue; arrows, synovial hypertrophy; <, growing cartilage; big arrow, bone.
fped-11-1102382-g001.jpg
PMC10063871_02_fped-11-1102382-g001.jpg
F1
Ultrasound confirmed the presence of joint effusion and synovial thickening (Figure 1), and synovial fluid analysis was consistent with inflammatory arthrosynovitis (white blood cell count of 14,200/microl) compatible with JIA.
Multimodal imaging of the left eye of a 7-year-old boy with Prader-Willi syndrome (case 2). Anterior segment slit-lamp photography (left) showed no granulomatous deposits and posterior synechiae. Spectral-domain optical coherence tomography + infrared reflectance (right) displayed macular anatomy and thickness within normal limits.
fped-11-1102382-g002.jpg
PMC10063871_02_fped-11-1102382-g002.jpg
F2
At the first eye evaluation, 1 month after the diagnosis of arthritis, a completed ophthalmological evaluation, including slit-lamp biomicroscopy, revealed the presence of inflammatory cells in the anterior chamber, posterior synechiae, band keratopathy, and initial cataract in both eyes (Figure 2), compatible with asymptomatic anterior bilateral uveitis.
Timeline of clinical manifestations and treatments. RnGH, recombinant human growth hormone; MTX, methotrexate. *Treatment with rhGH was temporally discontinued for 15 months due to a diagnosis of ganglioneuroma.
fped-11-1102382-g003.jpg
PMC10063871_02_fped-11-1102382-g003.jpg
F3
At the last follow-up, 9 months later, the child experienced inactivity of arthritis and uveitis with normal growth (Figure 3).